12/1
07:02 pm
psnl
Personalis (NASDAQ:PSNL) was given a new $11.00 price target on by analysts at Morgan Stanley.
Low
Report
Personalis (NASDAQ:PSNL) was given a new $11.00 price target on by analysts at Morgan Stanley.
11/27
10:37 pm
psnl
Personalis: A Growth Inflection Is Imminent, Hold [Seeking Alpha]
Low
Report
Personalis: A Growth Inflection Is Imminent, Hold [Seeking Alpha]
11/18
04:01 pm
psnl
Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference
Medium
Report
Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference
11/11
12:21 pm
psnl
Personalis (NASDAQ:PSNL) had its price target raised by analysts at Morgan Stanley from $5.00 to $9.00. They now have an "equal weight" rating on the stock.
Low
Report
Personalis (NASDAQ:PSNL) had its price target raised by analysts at Morgan Stanley from $5.00 to $9.00. They now have an "equal weight" rating on the stock.
11/11
09:06 am
psnl
Personalis (NASDAQ:PSNL) had its price target raised by analysts at Guggenheim from $6.00 to $12.00. They now have a "buy" rating on the stock.
Medium
Report
Personalis (NASDAQ:PSNL) had its price target raised by analysts at Guggenheim from $6.00 to $12.00. They now have a "buy" rating on the stock.
11/11
08:09 am
psnl
Personalis (NASDAQ:PSNL) had its price target raised by analysts at BTIG Research from $11.00 to $12.00. They now have a "buy" rating on the stock.
Low
Report
Personalis (NASDAQ:PSNL) had its price target raised by analysts at BTIG Research from $11.00 to $12.00. They now have a "buy" rating on the stock.
11/10
09:20 am
psnl
Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer [Yahoo! Finance]
High
Report
Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer [Yahoo! Finance]
11/10
09:00 am
psnl
Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer
High
Report
Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer
11/9
12:43 am
psnl
How the Story Behind Personalis Is Evolving After New Earnings and Guidance Updates [Yahoo! Finance]
High
Report
How the Story Behind Personalis Is Evolving After New Earnings and Guidance Updates [Yahoo! Finance]
11/6
08:10 am
psnl
Personalis (NASDAQ:PSNL) had its price target raised by analysts at HC Wainwright from $8.50 to $10.00. They now have a "buy" rating on the stock.
Medium
Report
Personalis (NASDAQ:PSNL) had its price target raised by analysts at HC Wainwright from $8.50 to $10.00. They now have a "buy" rating on the stock.
11/5
10:03 am
psnl
Personalis (NASDAQ:PSNL) had its "buy" rating reaffirmed by analysts at Lake Street Capital.
Low
Report
Personalis (NASDAQ:PSNL) had its "buy" rating reaffirmed by analysts at Lake Street Capital.
11/5
07:19 am
psnl
Personalis (NASDAQ:PSNL) had its "buy" rating reaffirmed by analysts at Needham & Company LLC.
Medium
Report
Personalis (NASDAQ:PSNL) had its "buy" rating reaffirmed by analysts at Needham & Company LLC.
11/4
04:01 pm
psnl
Personalis Reports Third Quarter 2025 Financial Results
Medium
Report
Personalis Reports Third Quarter 2025 Financial Results
10/25
11:38 am
psnl
How the Narrative Around Personalis Is Shifting After Recent Analyst Updates and Clinical Progress [Yahoo! Finance]
Medium
Report
How the Narrative Around Personalis Is Shifting After Recent Analyst Updates and Clinical Progress [Yahoo! Finance]
10/22
08:34 am
psnl
Personalis (NASDAQ:PSNL) had its price target raised by analysts at BTIG Research from $6.00 to $11.00. They now have a "buy" rating on the stock.
Medium
Report
Personalis (NASDAQ:PSNL) had its price target raised by analysts at BTIG Research from $6.00 to $11.00. They now have a "buy" rating on the stock.
10/21
04:01 pm
psnl
Personalis to Announce Third Quarter 2025 Financial Results
Medium
Report
Personalis to Announce Third Quarter 2025 Financial Results
10/16
09:00 am
psnl
Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing
High
Report
Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing
9/20
01:09 am
psnl
Low
Report
9/15
05:35 pm
psnl
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/10
04:18 pm
psnl
CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test [Yahoo! Finance]
High
Report
CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test [Yahoo! Finance]
9/10
04:05 pm
psnl
CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test
High
Report
CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test
9/8
08:05 am
psnl
Personalis (NASDAQ:PSNL) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $8.50 price target on the stock.
Low
Report
Personalis (NASDAQ:PSNL) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $8.50 price target on the stock.